Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Thirty-three University of Oxford researchers have been named Turing Fellows for the 2021/22 academic year, including eight from the Medical Sciences Division.

Slate statue of Alan Turing in Bletchley

The University’s cohort of fellows comprises researchers from 14 departments spanning the Mathematical, Physical, and Life Sciences (MPLS), Social Sciences and Medical Sciences divisions. Some have been closely involved with the Alan Turing Institute – the UK’s national institute for data science and AI – since its creation in 2015, when Oxford was one of the five founding university members; for the rest, the Fellowship is their first formal association with the Institute.

Fellows’ research interests range from the fundamentals of AI and development of novel methods to cutting-edge application of data science to real-world challenges in areas from seismology and volcanology to immunology, neuroscience, mental healthcare, and finance.

The eight Turing Fellows from the Medical Sciences Division are:

Read the full story on the University of Oxford website

Similar stories

Typhoid vaccine trial confirms sustained protection for older children

A single dose of typhoid conjugate vaccine (TCV) offers safe, effective protection against typhoid two years after vaccination in all children, and sustained protection for older children at three to five years post immunisation, according to a report by researchers at the Oxford Vaccine Group and the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b). But it also shows a decline in protection at the later timepoints among children vaccinated at younger ages.